Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease

Ayse Dudu Altintas Dogan; Ole Hilberg; Søren Hess; Torben Tranborg Jensen; Else Marie Bladbjerg; Claus Bogh Juhl

doi:10.2147/COPD.S350133

Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease

Ayse Dudu Altintas Dogan^*
, Ole Hilberg
, Søren Hess
, Torben Tranborg Jensen
, Else Marie Bladbjerg
, Claus Bogh Juhl

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › Research › peer-review

152 Downloads (Pure)

Abstract

Purpose: Chronic obstructive pulmonary disease (COPD) affects millions of people worldwide. Obesity is commonly seen concomitantly with COPD. People with COPD have reduced quality of life, reduced physical activity, chronic respiratory symptoms, and may suffer from frequent clinical exacerbations. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus. In addition, liraglutide exerts anti-inflammatory actions by reducing IL-6 and MCP-1 levels. We investigated the effect of liraglutide on pulmonary function in people suffering from obesity and COPD. Patients and Methods: In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks. At baseline and after 4, 20, 40, and 44 weeks, participants underwent pulmonary-function tests, 6-min walking test, and replied to a questionnaire regarding the clinical impact of COPD (COPD assessment test (CAT)-score). Results: Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score. We found no significant changes in forced expiratory volume in one second (FEV₁), FEV₁/FVC, or 6-min walking distance. Conclusion: In patients suffering from obesity and COPD, 40 weeks of treatment with liraglutide improved some measures of pulmonary function. Our study suggests that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD.

Original language	English
Journal	International Journal of Chronic Obstructive Pulmonary Disease
Volume	17
Pages (from-to)	405-414
ISSN	1178-2005
DOIs	https://doi.org/10.2147/COPD.S350133
Publication status	Published - 2022

Bibliographical note

Publisher Copyright:
© 2022 Altintas Dogan et al.

Funding

Study medication and running costs were provided by Novo Nordisk as a part of the Investigator Sponsored Studies Program. We also had financial support from Karola Jørgensens Forskningsfond, Research Council of Hospital South West Jutland, University Hospital of Southern Denmark, and Region of Southern Denmark. We grateful to the Open Patient data Explorative Network. We are indebted to the Unit for Thrombosis Research, Department of Clinical Biochemistry, in Hospital South West Jutland, University Hospital of Southern Denmark, Esbjerg, Denmark for handling blood samples and biochemical measurements. We are also thankful to the study nurses at Hospital South West Jutland and to Sygehus Lillebaelt for excellent technical assistance. We thank Jeppe Gram (MD, PhD) for invaluable scientific advice. Study medication and running costs were provided by Novo Nordisk as a part of the Investigator Sponsored Studies Program. We also had financial support from Karola J?rgensens Forskningsfond, Research Council of Hospital South West Jutland, University Hospital of Southern Denmark, and Region of Southern Denmark.

Keywords

COPD
GLP-1 RA
Inflammation
Obesity
Spirometry

Documents & Links

10.2147/COPD.S350133Licence: CC BY-NC

Open Access VersionFinal published version, 2.08 MBLicence: CC BY-NC

SDU Link

Check access to the material in SDU Library's search engine

1 Ph.D. thesis

Effects of Glucagon-like peptide-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease
Dudu Altintas Dogan, A., 15. Dec 2022, Syddansk Universitet. Det Sundhedsvidenskabelige Fakultet. 94 p.
Research output: Thesis › Ph.D. thesis

Open Access
File
187 Downloads (Pure)

Cite this

Altintas Dogan, A. D., Hilberg, O., Hess, S., Jensen, T. T., Bladbjerg, E. M., & Juhl, C. B. (2022). Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease, 17, 405-414. https://doi.org/10.2147/COPD.S350133

@article{eb0c8197cf7f41bfb77da4135fbc4507,

title = "Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease",

abstract = "Purpose: Chronic obstructive pulmonary disease (COPD) affects millions of people worldwide. Obesity is commonly seen concomitantly with COPD. People with COPD have reduced quality of life, reduced physical activity, chronic respiratory symptoms, and may suffer from frequent clinical exacerbations. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus. In addition, liraglutide exerts anti-inflammatory actions by reducing IL-6 and MCP-1 levels. We investigated the effect of liraglutide on pulmonary function in people suffering from obesity and COPD. Patients and Methods: In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks. At baseline and after 4, 20, 40, and 44 weeks, participants underwent pulmonary-function tests, 6-min walking test, and replied to a questionnaire regarding the clinical impact of COPD (COPD assessment test (CAT)-score). Results: Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score. We found no significant changes in forced expiratory volume in one second (FEV1), FEV1/FVC, or 6-min walking distance. Conclusion: In patients suffering from obesity and COPD, 40 weeks of treatment with liraglutide improved some measures of pulmonary function. Our study suggests that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD.",

keywords = "COPD, GLP-1 RA, Inflammation, Obesity, Spirometry",

author = "\{Altintas Dogan\}, \{Ayse Dudu\} and Ole Hilberg and S{\o}ren Hess and Jensen, \{Torben Tranborg\} and Bladbjerg, \{Else Marie\} and Juhl, \{Claus Bogh\}",

note = "Publisher Copyright: {\textcopyright} 2022 Altintas Dogan et al.",

year = "2022",

doi = "10.2147/COPD.S350133",

language = "English",

volume = "17",

pages = "405--414",

journal = "International Journal of Chronic Obstructive Pulmonary Disease",

issn = "1178-2005",

publisher = "Dove Medical Press",

}

Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease. / Altintas Dogan, Ayse Dudu; Hilberg, Ole ; Hess, Søren et al.
In: International Journal of Chronic Obstructive Pulmonary Disease, Vol. 17, 2022, p. 405-414.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease

AU - Altintas Dogan, Ayse Dudu

AU - Hilberg, Ole

AU - Hess, Søren

AU - Jensen, Torben Tranborg

AU - Bladbjerg, Else Marie

AU - Juhl, Claus Bogh

PY - 2022

Y1 - 2022

N2 - Purpose: Chronic obstructive pulmonary disease (COPD) affects millions of people worldwide. Obesity is commonly seen concomitantly with COPD. People with COPD have reduced quality of life, reduced physical activity, chronic respiratory symptoms, and may suffer from frequent clinical exacerbations. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus. In addition, liraglutide exerts anti-inflammatory actions by reducing IL-6 and MCP-1 levels. We investigated the effect of liraglutide on pulmonary function in people suffering from obesity and COPD. Patients and Methods: In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks. At baseline and after 4, 20, 40, and 44 weeks, participants underwent pulmonary-function tests, 6-min walking test, and replied to a questionnaire regarding the clinical impact of COPD (COPD assessment test (CAT)-score). Results: Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score. We found no significant changes in forced expiratory volume in one second (FEV1), FEV1/FVC, or 6-min walking distance. Conclusion: In patients suffering from obesity and COPD, 40 weeks of treatment with liraglutide improved some measures of pulmonary function. Our study suggests that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD.

AB - Purpose: Chronic obstructive pulmonary disease (COPD) affects millions of people worldwide. Obesity is commonly seen concomitantly with COPD. People with COPD have reduced quality of life, reduced physical activity, chronic respiratory symptoms, and may suffer from frequent clinical exacerbations. Liraglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for weight loss and treatment of type-2 diabetes mellitus. In addition, liraglutide exerts anti-inflammatory actions by reducing IL-6 and MCP-1 levels. We investigated the effect of liraglutide on pulmonary function in people suffering from obesity and COPD. Patients and Methods: In this controlled, double-blind trial, 40 people with obesity and COPD from two outpatient clinics were allocated randomly to receive liraglutide (3.0 mg, s.c.) or placebo (s.c.) for 40 weeks. At baseline and after 4, 20, 40, and 44 weeks, participants underwent pulmonary-function tests, 6-min walking test, and replied to a questionnaire regarding the clinical impact of COPD (COPD assessment test (CAT)-score). Results: Compared with placebo, liraglutide use resulted in significant weight loss, increased forced vital capacity (FVC) and carbon monoxide diffusion capacity, and improved CAT-score. We found no significant changes in forced expiratory volume in one second (FEV1), FEV1/FVC, or 6-min walking distance. Conclusion: In patients suffering from obesity and COPD, 40 weeks of treatment with liraglutide improved some measures of pulmonary function. Our study suggests that liraglutide at 3.0 mg may be appropriate treatment in patients with obesity and COPD.

KW - COPD

KW - GLP-1 RA

KW - Inflammation

KW - Obesity

KW - Spirometry

U2 - 10.2147/COPD.S350133

DO - 10.2147/COPD.S350133

M3 - Journal article

C2 - 35237033

AN - SCOPUS:85125205900

SN - 1178-2005

VL - 17

SP - 405

EP - 414

JO - International Journal of Chronic Obstructive Pulmonary Disease

JF - International Journal of Chronic Obstructive Pulmonary Disease

ER -

Respiratory Effects of Treatment with a Glucagon-Like Peptide-1 Receptor Agonist in Patients Suffering from Obesity and Chronic Obstructive Pulmonary Disease

Abstract

Bibliographical note

Funding

Keywords

Documents & Links

SDU Link

Fingerprint

Related research output

Effects of Glucagon-like peptide-1 receptor agonist treatment on pulmonary function and quality of life in obese patients with chronic obstructive pulmonary disease

Cite this